CA2391922A1 - Systemes porteurs comportant des substances enveloppantes avec groupes lateraux pouvant etre separes de maniere enzymatique - Google Patents

Systemes porteurs comportant des substances enveloppantes avec groupes lateraux pouvant etre separes de maniere enzymatique Download PDF

Info

Publication number
CA2391922A1
CA2391922A1 CA002391922A CA2391922A CA2391922A1 CA 2391922 A1 CA2391922 A1 CA 2391922A1 CA 002391922 A CA002391922 A CA 002391922A CA 2391922 A CA2391922 A CA 2391922A CA 2391922 A1 CA2391922 A1 CA 2391922A1
Authority
CA
Canada
Prior art keywords
component
binding structure
carrier system
binding
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002391922A
Other languages
English (en)
Inventor
Hans-Harald Sedlacek
Thomas Kissel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2391922A1 publication Critical patent/CA2391922A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un système porteur pouvant être obtenu (1) éventuellement par mélange d'une composante a2) avec une composante a1) dans le rapport molaire [a2):a1)] de 1:1 à 1000:1, de préférence entre 10:1 et 100:1, et (2) par mélange du complexe obtenu en (1) ou de la composante a1) seule avec une composante b1), de préférence dans le rapport molaire b1):a1) + évent. a2) de 1:1 bis 1:1000, le rapport du mélange étant réglé de manière que la charge nette du complexe total résultant soit neutre ou anionique. La composante a1) contient un agent actif a1), et une structure de liaison a1) pour les structures de liaison b1) ou a2), l'agent actif a1) pouvant contenir la structure de liaison a1) ; la composante a2) contient une structure de liaison a2) pour la structure de liaison a1), et un porteur a2) pouvant contenir la structure de liaison a2) ; et la composante b1) contient une structure de liaison b1) pour la structure de liaison a1), pour l'agent actif a1), pour la structure de liaison a2) ou pour le porteur a2), une substance enveloppante pouvant contenir la structure de liaison b1), une partie de liaison pouvant être séparée de manière enzymatique, et un groupe latéral anionique. L'invention concerne également la fabrication et l'utilisation dudit système support.
CA002391922A 1999-11-22 2000-11-09 Systemes porteurs comportant des substances enveloppantes avec groupes lateraux pouvant etre separes de maniere enzymatique Abandoned CA2391922A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19956029A DE19956029A1 (de) 1999-11-22 1999-11-22 Trägersysteme enthaltend Hüllsubstanzen mit enzymatisch abspaltbaren Seitengruppen
DE19956029.3 1999-11-22
PCT/EP2000/011055 WO2001038552A2 (fr) 1999-11-22 2000-11-09 Systemes porteurs comportant des substances enveloppantes avec groupes lateraux pouvant etre separes de maniere enzymatique

Publications (1)

Publication Number Publication Date
CA2391922A1 true CA2391922A1 (fr) 2001-05-31

Family

ID=7929842

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002391922A Abandoned CA2391922A1 (fr) 1999-11-22 2000-11-09 Systemes porteurs comportant des substances enveloppantes avec groupes lateraux pouvant etre separes de maniere enzymatique

Country Status (7)

Country Link
EP (1) EP1235922A2 (fr)
JP (1) JP2003514895A (fr)
AU (1) AU1520201A (fr)
CA (1) CA2391922A1 (fr)
DE (1) DE19956029A1 (fr)
MX (1) MXPA02004532A (fr)
WO (1) WO2001038552A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP1138334A3 (fr) * 1992-06-09 2002-04-03 Neorx Corporation Procédés et composés de préciblage
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
DE19743135A1 (de) * 1997-09-30 1999-04-01 Hoechst Marion Roussel De Gmbh Biologisch verträgliche niedermolekular Polyethylenimine

Also Published As

Publication number Publication date
AU1520201A (en) 2001-06-04
EP1235922A2 (fr) 2002-09-04
WO2001038552A3 (fr) 2002-03-28
MXPA02004532A (es) 2002-09-02
DE19956029A1 (de) 2001-05-23
WO2001038552A2 (fr) 2001-05-31
JP2003514895A (ja) 2003-04-22

Similar Documents

Publication Publication Date Title
US5908777A (en) Lipidic vector for nucleic acid delivery
Wang et al. pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse.
US5916803A (en) Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use
US5795587A (en) Stable lipid-comprising drug delivery complexes and methods for their production
CN100354426C (zh) 病毒核心蛋白－阳离子脂质－核酸－递送复合物
US20050025821A1 (en) Lipid-comprising drug delivery complexes and methods for their production
AU683400B2 (en) Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
EP0904100B1 (fr) Administration de molecules actives biologiquement, facilitee par un ligand a un recepteur et un lipide cationique
US6210708B1 (en) Cationic virosomes as transfer system for genetic material
KR19980702200A (ko) 핵산 함유 조성물과 이의 제조방법 및 용도
US6372720B1 (en) Liposome fusion and delivery vehicle
CN109453187B (zh) 具有双重酶敏感特性的抗体核酸药物偶联物及其制备方法和应用
JP2007145761A (ja) 細胞膜透過性ペプチド修飾多糖−コレステロールまたは多糖−脂質非ウイルス性ベクターおよびその製造方法
JP2002316997A (ja) 目的とするアニオン性物質を細胞に導入するための複合体
CA2474807A1 (fr) Peptides de transport et leurs utilisations
JP2002065278A (ja) Ｈｖｊの融合タンパク質を含有する遺伝子移入ビヒクル
CA2391922A1 (fr) Systemes porteurs comportant des substances enveloppantes avec groupes lateraux pouvant etre separes de maniere enzymatique
Smith et al. Gene therapy in heart disease
RU2537262C2 (ru) Молекулярные конъюгаты с поликатионным участком и лигандом для доставки в клетку и ядро клетки днк и рнк
AU4758300A (en) Novel liposomal vector complexes and their use in gene therapy
JPH09234069A (ja) 遺伝子導入用組成物及び該組成物を用いた遺伝子導入方法
White Novel Bioconjugate Strategies to Improve Nonviral Gene Deliver to Liver: Systematic Optimization of Multi-Component Delivery Vehicles
JP2004534004A (ja) ポリヌクレオチドを細胞へトランスフェクションするための組成物を製造するための非複合体化ペプチドの使用および遺伝子治療において有用な組成物
JP2003503362A (ja) 新規なベクター複合体および遺伝子治療のためのその使用
Montier et al. 481. Efficient gene transfer into human epithelial cell lines using glycosylated cationic carriers and neutral glycosylated co-lipids

Legal Events

Date Code Title Description
FZDE Dead